Israel has so far administered at least one of two recommended doses to more than half its nine million-strong population. The rapid rollout has allowed for shops to re-open and activities in public spaces to resume, some of which, such as sports centres, are reserved for people with a “green badge” indicating they’ve had two doses.The trip by the Austrian and Danish leaders to Israel was criticized by France, as the Elysee Palace maintained that European Union nations should stick together in developing anti-COVID vaccines. The European Commission stopped short from censuring the Israel-Austria-Denmark alliance. “We welcome the fact that member states are looking at all possible options to improve the common European response to the to the virus,” said EU Commission spokesman Eric Mamer. “For us, there is no contradiction,” he added, writes Yossi Lempkowicz.
Israeli Prime Minister Benjamin Netanyahu held on Thursday (4 March) a summit meeting in Jerusalem with Austrian Chancellor Sebastian Kurz and Danish Prime Minister Metter Frederiksen on a project to advance the establishment of a joint fund for the research, development and production of vaccines.
“Prime Minister Metter Frederiksen of Denmark and Chancellor Sebastian Kurz of Austria, welcome to Jerusalem. This is a special day when two dynamic European leaders come together to Jerusalem to discuss together how we continue the battle against COVID,’’ said Netanyahu as he welcomed the two European leaders.
‘’We’re going to do a joint R&D fund and discuss the production, the possibility of joint investment in productions of facilities for vaccines. I think this is great news, and I think it reflects a respect we have for each other and the belief, the confidence that we have in working together to protect the health of our peoples,” he said.
He spoke about tne establishment of a joint R&D fund of Israel, Austria and Denmark, and beginning joint efforts for common production of future vaccines.
‘’I think this is something that we have to do, because we’re going to probably need, I can’t say with certitude, but with very high probability, we’ll probably need protection for the future,’’ Netanyahu said.
‘’ I wouldn’t say that we’re rushing towards herd immunity, but we’re getting there and we’ll see how that works. I think Israel serves as a model for the world, and we’re discussing some of our experiences, sharing those experiences with our friends, and indeed you are two wonderful friends for Israel,’’ the Israeli premier said.
The move by the two EU member states comes amid rising anger over delays in ordering, approving and distributing vaccines that have left the EU 27 nations trailing far behind Israel’s world-beating vaccination campaign.
Austrian Chancellor Sebastian Kurz said it was right that the EU procures vaccines for its member states but the European Medicines Agency (EMA) had been too slow to approve them. He also lambasted pharmaceutical companies’ supply bottlenecks.
“We must therefore prepare for further mutations and should no longer be dependent only on the EU for the production of second-generation vaccines,” he said.
His Danish counterpart was also critical of the EU’s vaccine programme. “I don’t think it can stand alone, because we need to increase capacity. That is why we are now fortunate to start a partnership with Israel,” she told reporters on Monday.
Mette Frederiksen said the three countries “have been working very closely together” since the start of the pandemic.
The countries share a vision for the future that “timely access to vaccines will be critical for our societies in the years to come… We cannot allow us to be caught off guard once again. We have new mutations, maybe new pandemics and maybe new health crises will endanger our societies again.”
She said Denmark and Austria are “very inspired by Israel’s ability to roll out the vaccines” for the coronavirus so efficiently.
Chancellor Kurz hailed Netanyahu, who he said was one of the first to identify the great danger of the pandemic in early 2020 and was “maybe the main reason why we reacted quite early in Austria.”
Israel is also now “the first country in the world that shows that it is possible to defeat the virus,” he said. “The world is looking to Israel with admiration. Now, we have to prepare… for the next stages of the pandemic,” he added.
Kurz said vaccine production is a complex process, and as part of the partnership on production each country will focus on specific elements of the process.
Netanyahu said that “together we’re starting here something that I think will galvanize the imagination of the world.”
‘’Other countries have already called me and they’ve said that they want to be part of this effort,’’ he noted.
Earlier on Thursday, Netanyahu, Kurz and Frederkisken visited a gym in the city of Modi’in where they to monitored the coronavirus routine in Israel according to the green pass model.
The trip by the Austrian and Danish leaders to Israel was criticized by France, as the Elysee Palace maintained that European Union nations should stick together in developing anti-COVID vaccines.
“Our conviction remains very clear that the most effective solution to meet vaccination needs must continue to be based on the European framework,” said a spokesperson for the French foreign ministry.
But the European Commission stopped short from censuring the Israel-Austria-Denmark alliance.
“We welcome the fact that member states are looking at all possible options to improve the common European response to the to the virus,” said EU Commission spokesman Eric Mamer. “For us, there is no contradiction,” he added.
Mamer added that with 27 member states and a population of 450 million, ”the EU faces a much bigger challenge than Israel with a population of ten million.” ”It’s not as if you can take one model and simply stick it on the European Union and say:”That’s what you should be doing,” he said. ”Each country is in charge of its own vaccine rollout strategy,” he noted.
The Green Pass
“The ‘green pass’ is our way of trying to open places in Israel, to bring back to life everything that we know… doing it in a safe zone. It is not really a bubble that is completely safe, but it is safe as it can possibly be. We allow more people to enter events as long as they show at the entrance the green pass,” explained Dr Sharon Alroy-Preis, head of public health services at the Israeli health ministry, during a media briefing organised by Europe Israel Press Association on the country’s handling of the coronavirus pandemic and its speedy vaccination programme.
“300 people are now allowed in a theatre, and 500 in an open space. Soon more people will be accomodated at events. Next week restaurants will open with green pass so there is a gradual reopening but we are not doing something too soon or too fast,” she said.
She added: “Israel started with an ‘open sky strategy’ at first there were ‘green’ and ‘red’ countries based on the infection rate in those countries but countries can ‘move pretty rapidly from green to red’ . That route brought a ‘significant amount of disease’ into the country because people were not keeping isolation as much as we thought when they came back from abroad.”
Professor Ran Balicer, Chief Innovation Officer for Clalit, Israel’s largest health-care organization and a senior advisor to the Israeli Government and Prime Minister Office on the COVID-19 pandemic response, said: "We already see some indirect effects that those who are vaccinated are both protected…we are soon reaching the 90% target set by the government… therefore we can take more risks and chances …we are now actively opening up the economy through a set of dedicated procedures – what we call ‘green badge dependent settings."
Papua New Guinea: EU allocates €1 million to strengthen the resilience of the most vulnerable during COVID-19
The EU has mobilized €1 million in emergency aid from the Epidemics Tool to assist those affected by COVID-19 in Papua New Guinea. The number of cases has skyrocketed in the last month, pushing the country's already stretched health system to the limit. The funding will support the International Committee of the Red Cross to implement a six-month intervention focused on the most urgent needs such as increasing treatment capacity of public health care system, supporting local health authorities to scale up the response and providing assistance to vaccination campaigns. This emergency Epidemics Tool allows the EU to provide rapid funding in case of an epidemic outbreak in a humanitarian context.
How a WHO push for global vaccines needled Europe
Last April, at the start of the COVID-19 pandemic, European Commission President Ursula von der Leyen added Europe to a global effort to ensure equitable access to a vaccine, which she said would be deployed "to every single corner of the world", write Francesco Guarascio and John Chalmers.
But despite pledging billions of dollars for the scheme set up by the World Health Organization (WHO) and publicly endorsing it, European Union officials and member states repeatedly made choices that undermined the campaign, internal documents seen by Reuters and interviews with EU officials and diplomats show.
A year after its launch, Europe and the rest of the world have yet to donate a single dose through the vaccine scheme, which is part of an unprecedented effort to distribute vaccines, tests and drugs to fight the pandemic. Diplomats say Europe's ambivalence stemmed partly from short supplies and a slack start to the global campaign, but also from concerns that the EU's efforts would go unnoticed in a vaccine diplomacy war where highly publicised promises from China and Russia were winning ground, even in its own backyard.
The programme, co-led by international agencies and the Global Alliance for Vaccines and Immunization (GAVI), is a bulk-buying platform to share doses worldwide. But with the administration of former U.S. President Donald Trump having turned its back on the WHO, the plan, called COVAX, was slow to win support and focused on using funds from rich countries to buy doses for less-developed ones.
Von der Leyen presented Europe's support for the COVAX campaign as a gesture of international unity. EU officials privately cast the bloc's vaccine aims in a less altruistic light.
"It's also about visibility," that is, public relations, Ilze Juhansone, Secretary-General of the EU Commission and the Commission's top civil servant, told ambassadors at a meeting in Brussels in February, according to a diplomatic note seen by Reuters. Juhansone declined to comment.
A senior diplomat said many of those at that meeting felt Europe, which is by far the largest exporter of vaccines in the West, had goals that would be better served by plastering "more blue flags with yellow stars" on vaccine parcels and sending them out itself, rather than through COVAX.
Brussels, which is coordinating vaccine deals with its members, has reserved a huge surplus - 2.6 billion doses for a population of 450 million so far. It has promised nearly €2.5 billion ($3bn) in support to COVAX. That made the EU the biggest funder until the administration of US President Joe Biden pledged $4n this year to the plan, which aims to distribute 2 billion doses by the end of the year.
But supplies for Europe's own population are behind schedule, and despite giving funds, the EU and its 27 governments have also hampered COVAX in several ways. Like other rich countries, EU nations decided not to buy their own vaccines through COVAX, and competed with it to buy shots when supplies were tight. All except Germany offered the overall programme less cash than requested.
More than this, Europe promoted a parallel vaccine donation system that it would run itself, to raise the EU's profile.
"There is huge frustration because there is a feeling that right now the race is on but we're not really out of the starting blocks," a senior diplomat told Reuters.
"We're spending money on COVAX and the return in terms of political visibility is nil."
Russia says it wants to supply vaccines to countries directly. China has pledged support to COVAX. But both Moscow and Beijing have separate deals to deliver more than 1 billion doses to Africa, Latin America, and to EU partners such as Turkey, Egypt, Morocco and Balkan states that are candidates to join the bloc.
Most doses will take time to be delivered, but Russia and China have already exported about twice COVAX's deliveries of around 40 million doses.
COVAX was also hit in March by export restrictions on vaccines from India, which slowed supplies from its main provider of shots.
WHO chief Tedros Adhanom Ghebreyesus has repeatedly urged rich countries to set aside nationalistic impulses and share vaccines, calling the current situation "a shocking imbalance." Non-EU member Britain, for instance, has already injected about as many shots as COVAX has delivered to more than 100 countries.
COVAX officials told Reuters they received sufficient funds by the end of last year, but these came later than expected.
A spokeswoman for GAVI, the vaccine alliance that runs the scheme and speaks for COVAX on such issues, said EU support had been "unequivocal" and it expects doses to be donated soon. The WHO added that von der Leyen's personal support had been "invaluable."
An EU Commission spokesman told Reuters COVAX had been very successful in structuring global collaboration and securing millions of doses. He called the programme "our best vehicle to deliver on international vaccines solidarity" and the EU's "key channel for sharing vaccines."
Part of COVAX's difficulty is structural. Soon after it was set up, the wealthiest countries were sealing advance orders with drug companies to secure doses as they became available. The vaccination scheme has always relied on rich states for cash, which they have been slow to give.
COVAX aimed to be a platform for countries to buy vaccines, which would give it bargaining power and allow it to dispense doses among those most in need worldwide. Recognising supplies would be tight, its initial aim was to distribute doses for at least 20% of each country's populations to cover the people most at risk.
At an internal meeting last July, an EU Commission official told ambassadors that member states should not buy their shots through COVAX as they would come too slowly, diplomatic notes show. The Commission later set the target to vaccinate 70% of adults in the EU by the end of September.
COVAX changed some of its terms the next month to try to convince wealthy nations to join in, but no EU nations signed up to use the platform for their vaccination drives. The EU gave COVAX financial guarantees to pay for vaccines, but also made it harder for COVAX to do this, by arranging to buy far more doses than the bloc needed.
In November, the EU pledged more money to COVAX, but only after it had signed contracts with vaccine makers for nearly 1.5 billion doses - more than half Brussels' estimate then of global production capacity for this year, internal documents show.
Even though Europe had reserved such a large share, the Commission told diplomats in a meeting that month that COVAX was too slow in procuring doses.
That was when the Commission raised the possibility of setting up a mechanism of its own to send shots to poor countries outside the EU.
Within a month, France started to flesh out that plan. Shots would be sent directly from manufacturers - possibly before deliveries started through COVAX - and labelled as "Team Europe" donations, a draft plan said.
The move, revealed at the time by Reuters, caused an outcry among officials at COVAX. Read more
One told Reuters in April the plan was driven by France's desire to get shots to Africa, where France formerly had colonies, and smacked of colonialism. French diplomats said they never showed a preference for any country, and Africa was most in need.
EU Health Commissioner Stella Kyriakides said in mid-January the EU's own plan would go ahead - because COVAX was not yet fully operational. Countries to focus on would include the Western Balkans, the EU's southern and eastern neighbours and Africa.
The next month, having reserved more than 2 billion doses but with actual deliveries hit by production problems, the EU doubled COVAX funding to €1bn. Russia and China had already delivered millions of doses across the world. COVAX had yet to deliver any. And France's President Emmanuel Macron was publicly losing patience.
Europe and the United States should quickly send enough vaccines to Africa to inoculate the continent's healthcare workers or risk losing influence to Russia and China, Macron said in a speech at a security conference, without specifying how these donations should be made.
Unless rich countries speeded up deliveries, "our friends in Africa will, under justified pressure from their people, buy doses from the Chinese and the Russians," Macron told the conference. "And the strength of the West will be a concept, and not a reality." Read more
Despite Macron's urgency, France's cash support for the overall WHO programme - to cover tests and treatments as well as vaccines - was limited.
The WHO asked countries for contributions in proportion to their economic power. France has committed $190 million - about 13% of the $1.2 billion requested, a WHO document dated March 26 shows.
Other EU countries are also far below expected contributions; some have given zero. But Germany has helped offset this by publicly pledging $2.6bn, well above the $2bn requested.
French diplomats said the country's contributions are expected to increase soon.
On 24 February, COVAX shipped its first vaccines. The EU softened its criticisms.
At a meeting on 9 March, at the height of the European Union's own problems in procuring shots for its own citizens, a Commission official told diplomats COVAX was the main tool for donating vaccines to other countries.
But the official said Europe still needed its own mechanism, because COVAX had money, but only a tiny portion of the shots it needed. And the EU scheme would have "the advantage of giving us visibility," the official said.
At that same meeting, EU ambassadors were shown data compiled by the EU's foreign affairs service which those present said revealed how far the bloc's vaccine diplomacy was lagging behind its competitors.
They learned that Russia had orders for 645 million doses of its Sputnik V COVID-19 vaccine with dozens of countries, and that China was shipping millions of doses to EU neighbours, the data showed.
"We are completely out of this game," one of the diplomats who was there told Reuters.
Reuters could not confirm the data exactly. But figures assembled by the United Nations agency UNICEF, which works with COVAX on vaccine deliveries, show Russia has deals to deliver nearly 600 million doses, including to EU states. China has deals to sell about 800 million doses, including agreements with European countries such as Serbia, Ukraine and Albania.
Later that month the EU's top diplomat, Josep Borrell, made the point candidly: "The EU is the major driver behind COVAX," he wrote in a blog on 26 March. "But we do not get the recognition that the countries using bilateral vaccine diplomacy do."
On Tuesday, the EU Commission said the EU would share over half a million doses with Balkan countries from May through the EU scheme. That was two weeks after COVAX had delivered its first shots to the region. Read more
($1 = €0.8282)
EMA finds a possible - very rare - link to blood clots for Janssen vaccine
The European Medicines Agency (EMA) safety committee has concluded (20 April) that a warning about unusual blood clots with low blood platelets should be added to the product information for the COVID-19 Vaccine developed by Dutch company Janssen, also known as the Johnston and Johnson vaccine.
The new advice comes after eight reports of serious cases of unusual blood clots in the United States, which has already used this product to vaccinate more than seven million people. One of these cases resulted in a fatality. All cases occurred in people under 60 years of age within three weeks of vaccination, the majority in women. The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria.
It will be up to individual EU countries to decide whether they want to use this vaccine. The Janssen vaccine has the notable advantage of only requiring a single-shot, rather than a two-dose process.
The EMA are clear that the use of the vaccine continues to outweigh the risks for people who receive it. The vaccine is effective at preventing COVID-19 and reducing hospitalisations and deaths.
Immigration4 days ago
Asylum and migration in the EU: Facts and figures
EU4 days ago
EU-India: Boosting co-operation from trade to climate
coronavirus4 days ago
Merkel says lockdowns and curfews vital to break Germany's third wave
Alcohol4 days ago
Trends in alcohol consumption in Europe continue their positive course
EU4 days ago
EU and UK step up N. Ireland talks as EU continues legal action
coronavirus4 days ago
Europe must back Biden to lift vaccine patents, says Mary Robinson
Space4 days ago
Mars helicopter flight test promises Wright Brothers moment for NASA
Israel2 days ago
The time of Netanyahu comes to an end